VAISHALI
Vaishali Pharma financials
- Market cap
- ₹114 Cr
- Sector
- Healthcare
What Vaishali Pharma Limited does
Vaishali Pharma trades and markets Active Pharmaceutical Ingredients (APIs), pharmaceutical formulations, surgical products, veterinary supplements, herbal/nutraceutical products and oncology products for both human and animal health. It began in 1989 as an API trading company and expanded in 2012 into marketing formulations for a global clientele, now supplying domestic customers and exporting to international markets including Russia, D.R. Congo, Kenya and Vietnam. The company also manages domestic and international marketing operations for nutraceutical maker Sankalp Life Care under a strategic partnership, and supports its supply chain with a warehouse in Bhiwandi, Maharashtra.
Segments
- Active Pharmaceutical Ingredients (APIs)
- Pharmaceutical Formulations
- Surgical Products
- Veterinary Products
- Nutraceutical Products
- Oncology Products
- Export countries
- 40+
- Products (SKUs)
- 1,500+
- Brands
- 250+
- Customers
- 1,000+
- Locations (offices/warehouses)
- 35+
- Warehouse capacity (Bhiwandi, Maharashtra)
- 100+ tonnes
Quarterly results
| Line item | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|
| Revenue | 33 | 25 | 27 | 23 |
| EBITDA | 1 | 2 | -0 | 1 |
| Net profit | 1 | 1 | 0 | 2 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance −57.8% 1Y
1Y: ₹20.76 on 14 Oct 2024 → ₹8.77. High ₹20.76 (14 Oct 2024), low ₹5.98 (20 Mar 2026).
Balance sheet
| Year ending | FY26 |
|---|---|
| Equity capital | ₹26 Cr |
| Reserves | ₹43 Cr |
| Borrowings | ₹19 Cr |
| Other liabilities | ₹35 Cr |
| Total liabilities | ₹123 Cr |
| Fixed assets | ₹2 Cr |
| Capital work in progress | ₹0 Cr |
| Investments | ₹6 Cr |
| Other assets | ₹116 Cr |
| Total assets | ₹123 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jul 2026
Since Jun 2025, promoters added +4.22 pp while the public trimmed −4.22 pp. The shareholder count shrank 7% to 26,697.
- Promoters
- 30.5%
- Public
- 69.5%
Since Jun 2025
- Promoters +4.22 pp
- Public −4.22 pp
How it drifted, 12 quarters
Over this window promoters went from 26.6% to 30.5% — +3.9 pp.
Ownership split by quarter, oldest first. Dec '23: Promoters 26.6%, Public 73.4%.Mar '24: Promoters 26.3%, Public 73.7%.Jun '24: Promoters 26.3%, Public 73.7%.Sep '24: Promoters 26.3%, Public 73.7%.Dec '24: Promoters 26.3%, Public 73.7%.Mar '25: Promoters 26.3%, Public 73.7%.Jun '25: Promoters 26.3%, Public 73.7%.Sep '25: Promoters 26.3%, Public 73.7%.Dec '25: Promoters 31.6%, Public 68.4%.Mar '26: Promoters 31.6%, Public 68.4%.Jun '26: Promoters 31.6%, Public 68.4%.Jul '26: Promoters 30.5%, Public 69.5%.
Who bought this quarter
since Jun 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Kesar Pharma Limited newly disclosed 3.36% held
The same filing shows 6 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jul 2026 filing
Every holder of Vaishali Pharma Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.
| Holder | Stake | Change |
|---|---|---|
| Atul Arvindbhai Vasani | 23.07% | −0.80 pp |
| Sapan Anil Shah | 6.17% | unchanged |
| Jagruti Atul Vasani | 5.04% | −0.17 pp |
| Kesar Pharma Limited | 3.36% | newly disclosed |
| Nupur Anil Shah | 3.16% | −0.11 pp |
| Renu Pittie | 1.68% | −0.06 pp |
| Sonal Sanjay Mirani | 1.52% | −0.05 pp |
| Sanjay Girdharilal Mirani | 1.48% | −0.05 pp |
| Kirit Chimanlal Tolia | 1.26% | unchanged |
| Dewansh Ajay Vasani | 0.74% | unchanged |
| Priyanka Atul Vasani | 0.74% | unchanged |
| Bharti Kiritkumar Tolia | 0.53% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
- Growth the price implies
- 26.6% a year
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Learn to analyse Vaishali Pharma Limited
Guides on how to read this kind of business and the numbers that matter.